• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, December 16, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Flavonoids as P-gp inhibitors: A systematic review of SARs

Bioengineer by Bioengineer
December 26, 2018
in Health
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

This article by Dr. Jiahua Cui et al. is published in Current Medicinal Chemistry, 2018

ABCB1 in the ABC transporter family also termed as P-glycoprotein, grants the simultaneous resistance of metastatic cancer cells towards various anti-cancer drugs with different targets and diverse chemical structures. For the past four decades, researchers have tried to search for safe and specific inhibitors of this pump. Naturally occurring flavonoids as benzopyrone derivatives are an example of non-toxic inhibitors of P-gp. In reversing multidrug resistance both in vitro and in vivo, the recent advent of synthetic flavonoid dimer FD18, as a potent P-gp modulator plays is also known. FD18 specifically targets the pseudodimeric structure of the drug transporter. These molecules represent a new generation of inhibitors with high transporter binding affinity and low toxicity.

This review focuses upon the current updates on the structure-activity relationships of flavonoids, the molecular mechanisms of their action and their ability to overcome P-gp-mediated MDR in preclinical studies. It presents crucial implications on the discovery of new drug candidates that modulated the efflux of ABC transporters and also provides some clues for the future development of flavonoid based pharmaceuticals that act as P-gp inhibitors.

###

To obtain the article, please visit: http://www.eurekaselect.com/165770

Media Contact
Faizan ul Haq
[email protected]
http://dx.doi.org/10.2174/0929867325666181001115225

Tags: BiochemistryBreast CancercancerCarcinogensMedicine/HealthPharmaceutical SciencesProstate CancerToxicology
Share12Tweet8Share2ShareShareShare2

Related Posts

Smart Nutritional App Enhances Malnutrition Care for Kids

December 16, 2025

Medical Debt: A Policy Making Patients Unwell

December 16, 2025

IBI318 Plus Lenvatinib Tackles Resistant Lung Cancer

December 16, 2025

Nanomedicine Breakthroughs Revolutionizing Lymphoma Treatment

December 16, 2025
Please login to join discussion

POPULAR NEWS

  • Scientists Uncover Chameleon’s Telephone-Cord-Like Optic Nerves, A Feature Missed by Aristotle and Newton

    Scientists Uncover Chameleon’s Telephone-Cord-Like Optic Nerves, A Feature Missed by Aristotle and Newton

    122 shares
    Share 49 Tweet 31
  • Nurses’ Views on Online Learning: Effects on Performance

    69 shares
    Share 28 Tweet 17
  • NSF funds machine-learning research at UNO and UNL to study energy requirements of walking in older adults

    70 shares
    Share 28 Tweet 18
  • MoCK2 Kinase Shapes Mitochondrial Dynamics in Rice Fungal Pathogen

    71 shares
    Share 28 Tweet 18

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Smart Nutritional App Enhances Malnutrition Care for Kids

Medical Debt: A Policy Making Patients Unwell

IBI318 Plus Lenvatinib Tackles Resistant Lung Cancer

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 69 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.